Search
01/05/2026
European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage
Vergouwen, MDI, Ramos-Pachon, A, Terecoasa, EO, Willett, N, Cuadrado-Godia, E, Gaberel, T, Gizewski, ER, Helbok, R, Ho, LA, Hugelshofer, M, Korja, M, Meling, TR, Psychogios, MN, Rinkel, GJE, Taschner, CA, Vajkoczy, P, Etminan, N. European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage. European Stroke Journal. 2026; 11(5)DOI:10.1093/esj/aakag043. PMID:42095754. IF:4.500(Q1/2D).
01/05/2026
KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs
Volta-Durán, E, Alba-Castellon, L, Arena, LA, Sánchez, JM, Casanova, I, Mangues, R, Villaverde, A, Vázquez, E, Unzueta, U. KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2026; 222DOI:10.1016/j.ejpb.2026.115020. PMID:41690333. IF:4.300(Q1/2D).
01/05/2026
Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026)
Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026). ADVANCES IN THERAPY. 2026; 43(5)DOI:10.1007/s12325-026-03532-4. PMID:41817916. IF:4.000(Q1/3D).
01/05/2026
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
Behrens, GMN, Assoumou, L, Liegeon, G, Antinori, A, Micán, R, Genderini, FG, Post, FA, Rockstroh, JK, Hamzah, L, Domingo, P, Curran, A, Laguno, M, Fletcher, C, Moody, J, Pozniak, A. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. LANCET INFECTIOUS DISEASES. 2026; 26(5)DOI:10.1016/S1473-3099(25)00681-4. PMID:41344354. IF:31.000(Q1/1D).
01/05/2026
Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases
Novello, S, Rabinovich, NM, Shih, JY, Pelizzari, G, Stevenson, J, Majem, M, Ferreira, CG, Petty, WJ, Arriola, E, Castagneris, N, De Castro, J, Morbeck, I, Bauman, J, Toschi, L, Zer, A, Metro, G, Kalmadi, S, Martinez, AA, Al Husaini, H, Meloni, AR, Nduka, C, Ardito-Abraham, C, Xia, CH, Awad, MM. Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases. Jto Clinical And Research Reports. 2026; 7(5)DOI:10.1016/j.jtocrr.2026.100974. PMID:42006282. IF:(Q/D).
01/05/2026
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical & Translational Oncology. 2026; 28(5)DOI:10.1007/s12094-025-04098-3. PMID:41313559. IF:2.500(Q3/6D).